Pharma

“Trojan Horse” Antibody to Treat Cancers Reaches New Test Stage

Toxic antibody tisutumab vedotin (TV) has shown promise as a treatment for a number of types of advanced cancer. This “trojan horse” approach has now reached the stage of being tested on a wider variety of patients. Institute of Cancer Research and Royal Marsden NHS Foundation Trust researchers tested the drug on 147 patients to evaluate potential benefits and side effects.

J&J is First Pharma Giant to Advertise Drug Prices on TV

Johnson and Johnson has vowed to become the first pharmaceutical giant to add its medicine prices to television adverts, starting in March 2018. The company said it will list not only product price before rebates or discounts, as well as potential out-of-pocket costs which patients will pay.

Festival of Genomics 2019 – The State of Genomics Today

The introduction of multi-omic research, the advancement of AI and machine learning to improve nearly every aspect of sequencing and data analysis, are just some of the big changes that will only become more prevalent in the future. We spoke to Angela Douglas MBE, Scientific Director of Genetics Laboratories at Liverpool Women’s Hospital, for her opinions on the changing nature of genomics and the trends to watch out for.

Festival of Genomics 2019 – Festival Highlights

With so many talks and panels occurring across our four stages and Live Lounge, we understand that it can be pretty hard to pick out the most unmissable discussions at the festival this year. Given the conundrum, we thought we’d help out! We’ve selected a couple of talks and panels occurring across the two days which we think will be incredibly interesting and enormously informative for a whole range of people.

Festival of Genomics 2019 – The Importance of Data Integration in the Pharma Industry

Data integration has been one of the major trends of the last few years, and one which will become ever-more important as the life sciences sectors progress further. Dr. Maya Ghoussaini, Genetic Analysis Team Leader at the Wellcome Sanger Institute, and Dr. Denise Carvalho-Silva, Scientific Outreach Lead at EMBL-EBI, both working at Open Targets, here discuss the importance of this process, and their own work within the realm of data integration.

Festival of Genomics 2019: The Survival Guide

With just under two weeks till the festival, it’s time to start thinking logistics. The more scatter-brained of our readers needn’t worry, however: we’ve got everything you need covered in this handy guide, whether it’s things to remember before you arrive at the festival, the best things to do once there and the last couple of things to remember when it’s all done.

Bristol-Myers Squibb to Buy Celgene for $74bn

Bristol-Myers Squibb (BMS) has announced intentions to buy Celgene for $74bn. This transaction, the fourth largest such deal in pharma history, will give BMS access to several cancer franchises, including experimental cell therapies which attack tumours.

Most Orphan Drugs Performing Poorly, Report Finds

The latest annual report from Trinity Partners has found that orphan disease drugs often perform poorly at launch and continue to underachieve after three years of sales. At the other end of the spectrum, the most successful drugs on the market were for non-orphan diseases such as cancer and HIV.